GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Sale Of Investment

Repligen (FRA:RGN) Sale Of Investment : €0.0 Mil (TTM As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Repligen Sale Of Investment?

Repligen's sale of investment for the three months ended in Mar. 2025 was €0.0 Mil. It means Repligen gained €0.0 Mil from selling investments. Repligen's sale of investment for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Dec. 2024 ), Repligen gained the same money from selling investments in Mar. 2025 (€0.0 Mil).


Repligen Sale Of Investment Historical Data

The historical data trend for Repligen's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Sale Of Investment Chart

Repligen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 93.83 -

Repligen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Repligen Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Repligen Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Repligen's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Headlines

No Headlines